Holly K. Tabor, PhD and Aaron Goldenberg, PhD, MPH
Rare genetic disease research has something to teach precision medicine about addressing some patients’ limited access to treatment. Health disparities exacerbated by high costs and limited availability of drugs can, perhaps, be mitigated when patient activism accelerates drug development.
AMA J Ethics. 2018;20(9):E834-840. doi:
10.1001/amajethics.2018.834.
Rebekah Davis Reed, PhD, JD and Erik L. Antonsen, PhD, MD
Though the National Aeronautics and Space Administration’s collection of disaggregated genetic data for occupational surveillance and research raises numerous privacy concerns, the Genetic Information Nondiscrimination Act of 2008 allows genetic information to be used to develop personal pharmaceuticals.
AMA J Ethics. 2018;20(9):E849-856. doi:
10.1001/amajethics.2018.849.
The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention.
AMA J Ethics. 2021;23(1):E49-54. doi:
10.1001/amajethics.2021.49.
Dr Daphne Mlachila joins Ethics Talk to discuss her article: “How Should Clinicians and Researchers in Government Respond to Threats to Their Offices?”
Professor Wendy E. Parmet joins Ethics Talk to discuss her article, coauthored with Dr Claudia E. Haupt: “Holding Clinicians in Public Office Accountable to Professional Standards.”
Dr Isabelle Freiling joins Ethics Talk to discuss her article, coauthored with Nicole M. Krause and Dr Dietram A. Scheufele: “Science and Ethics of ‘Curing’ Misinformation.”